RXi Pharmaceuticals - RXII Stock Forecast, Price & News

RXi Pharmaceuticals Co. (NASDAQ:RXII) announced its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.16. The biotechnology company earned $0.06 million during the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%.

RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and

RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII."

One share of RXII stock can currently be purchased for approximately $0.76.

RXi Pharmaceuticals (NASDAQ:RXII) has a market capitalization of $3.35 million and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The official website for the company is www.rxipharma.com. The biotechnology company can be reached via phone at (508) 767-3861 or via email at tmcgrillen@rxipharma.com.